Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IciCLLe
ISRCTN12695354Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of ibrutinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by University of Birmingham. Primary endpoint: MRD-negative remission rate. Started Apr 2014; status: completed.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN12695354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12695354.